Sonova Holding AG Stock (CH0012549785): Shareholders Back Record Dividend At 2026 AGM

At Sonova Holding AG's 41st Annual General Meeting on June 16, 2026, shareholders approved all board proposals, including a record CHF 4.70 dividend per share. The Swiss hearing-care group remains in focus for income-oriented investors.

Responsible: ad hoc news Companies & Analysis Desk. Reviewed prior to publication on June 16, 2026 at 9:57 PM ET. Details in the imprint.

Sonova Holding AG is drawing investor attention after shareholders signed off on all motions from the board of directors at the company’s 41st Annual General Meeting in Stafa, Switzerland, including a record cash dividend of CHF 4.70 per registered share for the 2025/26 financial year, equivalent to a payout ratio of around 45 percent and scheduled for payment from June 23, 2026.

According to the company, 354 shareholders were physically present at the 2026 AGM, with a total of 67.84 percent of the share capital represented, underscoring solid investor participation as the group confirmed its latest financial statements and compensation framework.

On the Swiss market, Sonova shares trade on SIX Swiss Exchange under the ticker symbol SOON and have been listed there since 1994, with the stock recently quoted around CHF 201.00, modestly higher on the day of the AGM amid a generally steady Swiss blue-chip environment.

Record dividend and strong AGM backing set the tone for Sonova

Sonova reported that shareholders approved the Annual Report, the consolidated financial statements of the Group, the standalone financial statements of Sonova Holding AG, and the report on non-financial matters for the 2025/26 business year, effectively endorsing the company’s latest operating and financial performance.

The centerpiece of the 2026 AGM was the decision to distribute a gross dividend of CHF 4.70 per registered share, described by Sonova as the highest dividend in the company’s history and representing a payout ratio of around 45 percent of earnings, positioning the group as an increasingly income-friendly name in the European medical technology space.

Sonova stated that the dividend will be paid from June 23, 2026, following the customary ex-dividend and record dates under Swiss market practice, giving existing shareholders a near-term cash return while the company continues to invest in hearing solutions and cochlear implant technologies.

In addition to the dividend decision, shareholders formally granted discharge to the members of the Board of Directors and the Group Executive Board for their conduct in the 2025/26 financial year, signaling broad support for the company’s strategic direction and governance during a period of ongoing demand for audiological products and services.

The AGM minutes highlight that advisory votes on the Compensation Report received backing from investors, and binding votes approved future compensation for both the Board of Directors and the Group Executive Board, indicating that Sonova’s pay structures currently align with shareholder expectations in terms of performance linkage and market competitiveness.

Sonova also used the 2026 AGM to renew key mandates at the top of the company, with shareholders re-electing existing directors and approving additional independent members to the Board, while confirming Ernst & Young AG as external auditor and Keller AG as the independent proxy, thereby maintaining continuity in oversight and auditing functions.

The company’s investor communication notes that a total of 354 shareholders attended the meeting in person, with 67.84 percent of the registered share capital represented, a participation level that reflects continued engagement from institutional holders as well as private investors in the Swiss and broader European markets.

For Sonova, the 45 percent payout ratio for 2025/26 sits comfortably within a typical range for mature, cash-generating healthcare equipment providers and balances shareholder remuneration with the need to finance research, development, and potential acquisitions in hearing aids, implants, and audiological care networks.

Market data from Swiss equity commentary indicates that Sonova shares recently closed around CHF 201.00, with a modest 0.20 percent gain on the session and a medium-term analyst consensus price target in the area of CHF 216.51, suggesting that the stock trades at a discount to the average target implied by covering analysts.

On German trading venues, where Sonova is also followed by retail investors, the stock has recently changed hands around EUR 232.00, up about 1.6 percent on the day referenced, reflecting currency effects and cross-border interest in the Swiss hearing-care specialist.

The next Annual General Meeting has already been scheduled for June 15, 2027, giving investors a clear timetable for when the company’s governance and capital allocation policies will again come up for a formal vote, barring any extraordinary shareholder meetings in the interim.

From a corporate governance perspective, reaffirming Ernst & Young AG as external auditor and Keller AG as independent proxy means that Sonova continues to rely on established partners for audit quality and the handling of institutional voting instructions, both of which are important to large asset managers with positions in Swiss mid and large caps.

Within the industry context, Sonova positions itself as a leading provider of innovative hearing solutions, including behind-the-ear and in-the-ear hearing aids, cochlear implants, and wireless communication accessories, operating a mix of wholesale distribution and retail audiological care channels across key markets in Europe, North America, and Asia-Pacific.

The group’s AGM release emphasizes ongoing investment in research and development aimed at improving sound quality, battery life, and connectivity in its product lines, as well as expanding service offerings through its network of hearing care professionals, which together support the company’s ability to sustain its dividend while pursuing growth.

For income-focused investors tracking European healthcare names, the combination of a record dividend, stable governance, and visible cash generation may make Sonova a noteworthy case study in how medical technology firms balance shareholder returns with innovation-led spending.

Against this backdrop, the 2026 AGM outcomes position Sonova for another year of executing on its hearing health strategy, with shareholders having reaffirmed their confidence in the board, management team, and capital allocation framework.

Sonova at a glance for stock watchers

• Name: Sonova Holding AG
• Industry: Hearing care, medical technology
• Headquarters: Stafa, Switzerland
• Core markets: Europe, North America, Asia-Pacific
• Revenue drivers: Hearing aids, cochlear implants, audiological care services, wireless communication solutions
• Listing: SIX Swiss Exchange, ticker SOON
• Trading currency: Swiss franc (CHF)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.